IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

INTRODUCTION: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). METHODS: The PROTECT tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Barratt, Jonathan, Rovin, Brad, Wong, Muh Geot, Alpers, Charles E., Bieler, Stewart, He, Ping, Inrig, Jula, Komers, Radko, Heerspink, Hiddo J.L., Mercer, Alex, Noronha, Irene L., Radhakrishnan, Jai, Rheault, Michelle N., Rote, William, Trachtman, Howard, Trimarchi, Hernán, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166729/
https://www.ncbi.nlm.nih.gov/pubmed/37180506
http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166729/
https://www.ncbi.nlm.nih.gov/pubmed/37180506
http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Ejemplares similares